Dr. James E. Race
Internal Medicine (Internal Medicine Physician)
- Medicare participating
At a glance
- Medical school
- Meharry Medical College School of Medicine (1984)
- Years since graduation
- 42
- In the NPI registry since
- 2006
- Medicare patients seen, 2024
- 144
Licensed in Texas since 1988, according to the Texas Medical Board. We show license dates only for the states that publish them in bulk; see which states do. For other states, check the state medical board.
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 1984Medical school: Meharry Medical College School of Medicine
- 2006Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Internal Medicine Physician primary
TX license H5039 (first issued 1988; active)
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Medical groups
- American Visiting Doctors, LLC (3 clinicians)
- Home Visiting Doctors Management LLC (3 clinicians)
- Phillips Family Medical PLLC (2 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 144
- Services billed
- 946
- Patients’ average age
- 71
| Service | Times | Patients |
|---|---|---|
| Physician or allowed practitioner re-certification for medicare-covered home health services under a home health plan of care (patient not present), including contacts with home health agency and review of reports of patient status required by physicians a | 271 | 73 |
| Chronic care management services, first 20 minutes of clinical staff time directed by health care professional, per calendar month | 168 | 35 |
| Established patient office or other outpatient visit, 20-29 minutes | 137 | 65 |
| Established patient office or other outpatient visit, 30-39 minutes | 119 | 72 |
| Blood glucose (sugar) test performed by hand-held instrument | 54 | 33 |
| Insertion of needle into vein for collection of blood sample | 45 | 38 |
| Annual wellness visit, includes a personalized prevention plan of service (pps), subsequent visit | 37 | 37 |
| Annual depression screening, 5 to 15 minutes | 31 | 31 |
| Urinalysis, manual test | 26 | 11 |
| Established patient office or other outpatient visit, 10-19 minutes | 17 | 15 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 10 companies reported 27 payments worth $690 in total to this clinician.
| AstraZeneca Pharmaceuticals LP | $255 |
|---|---|
| Novo Nordisk Inc | $112 |
| Corcept Therapeutics | $81.31 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $63.90 |
| Lilly USA, LLC | $56.30 |
| Exact Sciences Corporation | $54.56 |
| Shield Therapeutics Inc | $23.37 |
| Astellas Pharma US Inc | $15.00 |
| Food and Beverage | $690 |
|---|
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 1 industry-funded study in 2025, from 1 company. The companies reported $49,796 in research payments for these studies, mostly to the institutions running them.
- A Study to Investigate the Effect of Lepodisiran on the Reduction of Major Adverse Cardiovascular Events in Adults With Elevated Lipoprotein(a) - ACCLAIM-Lp(a)
Eli Lilly and Company · Active, not recruiting · NCT06292013
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.